Biotech | September 03, 2021
Omeza Collegen Matrix gets U.S. FDA approval
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
The drug is also intended for the treatment of glioblastoma multiforme
The segment delivered strong sales growth of 20% YoY
The facility has the capacity to produce one crore doses per day
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Domestic business was up 41.9% YoY and 27.7% QoQ
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Subscribe To Our Newsletter & Stay Updated
